Trials / Conditions / Burkitt's Lymphoma

Burkitt's Lymphoma

21 registered clinical trials studyying Burkitt's Lymphoma — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Active Not Recruiting	19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers NCT04464200	Memorial Sloan Kettering Cancer Center	Phase 1
Completed	UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep NCT02722668	Masonic Cancer Center, University of Minnesota	Phase 2
Completed	Allo HSCT Using RIC for Hematological Diseases NCT02661035	Masonic Cancer Center, University of Minnesota	Phase 2
Recruiting	Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases NCT01962636	Masonic Cancer Center, University of Minnesota	N/A
Completed	Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) NCT02669017	ADC Therapeutics S.A.	Phase 1
Terminated	Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases NCT02145039	Masonic Cancer Center, University of Minnesota	N/A
Withdrawn	T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies NCT01163201	Masonic Cancer Center, University of Minnesota	Phase 1 / Phase 2
Completed	Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Ad NCT01809600	Gachon University Gil Medical Center	—
Completed	Treatment for Advanced B-Cell Lymphoma NCT01859819	New York Medical College	Phase 2
Completed	Double Cord Versus Haploidentical (BMT CTN 1101) NCT01597778	Medical College of Wisconsin	Phase 3
Completed	Safety and Tolerability of HSC835 in Patients With Hematological Malignancies NCT01474681	Novartis Pharmaceuticals	Phase 1 / Phase 2
Completed	Short Term Intensified Chemo-immunotherapy in HIV-positive Patients With Burkitt Lymphoma NCT01516593	Andres J. M. Ferreri	Phase 2
Completed	MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincrist NCT01397825	Millennium Pharmaceuticals, Inc.	Phase 1 / Phase 2
Completed	Imexon for Relapsed Follicular and Aggressive Lymphomas NCT01314014	University of Rochester	Phase 2
Completed	Observational Study for the Cytofluorimetric Analysis of Cerebrospinal Fluid in Non-Hodgkin's Lymphoma Patient NCT00949741	Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie	—
Completed	Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma NCT00807495	Millennium Pharmaceuticals, Inc.	Phase 2
Terminated	Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies NCT00776373	Abramson Cancer Center at Penn Medicine	Phase 1 / Phase 2
Completed	Rituximab Combined With Chemotherapy in Burkitt's Lymphoma NCT00388193	PETHEMA Foundation	Phase 2
Completed	Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients NCT00412243	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Completed	Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burk NCT00669877	M.D. Anderson Cancer Center	Phase 2
Completed	Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in Adults NCT00199082	Nicola Goekbuget	Phase 4